JP6307314B2 - Oral stain formation inhibitor and oral composition - Google Patents
Oral stain formation inhibitor and oral composition Download PDFInfo
- Publication number
- JP6307314B2 JP6307314B2 JP2014050281A JP2014050281A JP6307314B2 JP 6307314 B2 JP6307314 B2 JP 6307314B2 JP 2014050281 A JP2014050281 A JP 2014050281A JP 2014050281 A JP2014050281 A JP 2014050281A JP 6307314 B2 JP6307314 B2 JP 6307314B2
- Authority
- JP
- Japan
- Prior art keywords
- oral
- stain formation
- stain
- formation inhibitor
- sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000015572 biosynthetic process Effects 0.000 title claims description 42
- 239000000203 mixture Substances 0.000 title claims description 20
- 239000003112 inhibitor Substances 0.000 title claims description 17
- 230000005764 inhibitory process Effects 0.000 claims description 12
- 210000000214 mouth Anatomy 0.000 claims description 12
- RUTSRVMUIGMTHJ-UHFFFAOYSA-M sodium;tetradec-1-ene-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCC=CS([O-])(=O)=O RUTSRVMUIGMTHJ-UHFFFAOYSA-M 0.000 claims description 9
- 238000012360 testing method Methods 0.000 description 31
- -1 mouth fresheners Substances 0.000 description 14
- 230000002401 inhibitory effect Effects 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 235000014113 dietary fatty acids Nutrition 0.000 description 8
- 239000000194 fatty acid Substances 0.000 description 8
- 229930195729 fatty acid Natural products 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000002324 mouth wash Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 230000007794 irritation Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 229940051866 mouthwash Drugs 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 235000021317 phosphate Nutrition 0.000 description 4
- 239000000606 toothpaste Substances 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- 235000006468 Thea sinensis Nutrition 0.000 description 3
- 235000020279 black tea Nutrition 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 150000005215 alkyl ethers Chemical class 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- FRHBOQMZUOWXQL-UHFFFAOYSA-K azane;2-hydroxypropane-1,2,3-tricarboxylate;iron(3+) Chemical compound N.[Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FRHBOQMZUOWXQL-UHFFFAOYSA-K 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 2
- 229960001950 benzethonium chloride Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 2
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 2
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 2
- 239000004313 iron ammonium citrate Substances 0.000 description 2
- 235000000011 iron ammonium citrate Nutrition 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- QYIXCDOBOSTCEI-QCYZZNICSA-N (5alpha)-cholestan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-QCYZZNICSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- NGOZDSMNMIRDFP-UHFFFAOYSA-N 2-[methyl(tetradecanoyl)amino]acetic acid Chemical compound CCCCCCCCCCCCCC(=O)N(C)CC(O)=O NGOZDSMNMIRDFP-UHFFFAOYSA-N 0.000 description 1
- XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 description 1
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 241000219310 Beta vulgaris subsp. vulgaris Species 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- 244000302899 Cassia mimosoides Species 0.000 description 1
- 235000014112 Cassia mimosoides Nutrition 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical class C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 240000007154 Coffea arabica Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 235000021536 Sugar beet Nutrition 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000005211 alkyl trimethyl ammonium group Chemical group 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 1
- QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002272 anti-calculus Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 229960004830 cetylpyridinium Drugs 0.000 description 1
- NEUSVAOJNUQRTM-UHFFFAOYSA-N cetylpyridinium Chemical compound CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 NEUSVAOJNUQRTM-UHFFFAOYSA-N 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229930007050 cineol Natural products 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- 239000010630 cinnamon oil Substances 0.000 description 1
- 235000016213 coffee Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- FPAYXBWMYIMERV-UHFFFAOYSA-L disodium;5-methyl-2-[[4-(4-methyl-2-sulfonatoanilino)-9,10-dioxoanthracen-1-yl]amino]benzenesulfonate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)C1=CC(C)=CC=C1NC(C=1C(=O)C2=CC=CC=C2C(=O)C=11)=CC=C1NC1=CC=C(C)C=C1S([O-])(=O)=O FPAYXBWMYIMERV-UHFFFAOYSA-L 0.000 description 1
- QYIXCDOBOSTCEI-FBVYSKEZSA-N epidihydrocholesterin Chemical compound C([C@@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-FBVYSKEZSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000004673 fluoride salts Chemical class 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 229950002760 sodium gualenate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229960004711 sodium monofluorophosphate Drugs 0.000 description 1
- URLJMZWTXZTZRR-UHFFFAOYSA-N sodium myristyl sulfate Chemical compound CCCCCCCCCCCCCCOS(O)(=O)=O URLJMZWTXZTZRR-UHFFFAOYSA-N 0.000 description 1
- 229950005425 sodium myristyl sulfate Drugs 0.000 description 1
- GEYJUFBPCGDENK-UHFFFAOYSA-M sodium;3,8-dimethyl-5-propan-2-ylazulene-1-sulfonate Chemical compound [Na+].CC(C)C1=CC=C(C)C2=C(S([O-])(=O)=O)C=C(C)C2=C1 GEYJUFBPCGDENK-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229940104261 taurate Drugs 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- UJMBCXLDXJUMFB-UHFFFAOYSA-K trisodium;5-oxo-1-(4-sulfonatophenyl)-4-[(4-sulfonatophenyl)diazenyl]-4h-pyrazole-3-carboxylate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-UHFFFAOYSA-K 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 229940117960 vanillin Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 229930007845 β-thujaplicin Natural products 0.000 description 1
Landscapes
- Cosmetics (AREA)
Description
本発明は、口腔用ステイン形成阻害剤および口腔用組成物に関する。 The present invention relates to an oral stain formation inhibitor and an oral composition.
ステインは、コーヒー、紅茶、日本茶等に含まれるタンニン色素、喫煙、口腔内のタンパク質、金属イオン等が原因となって歯牙表面に形成される色素沈着物である。 Stain is a pigment deposit formed on the tooth surface due to tannin pigments, smoking, proteins in the oral cavity, metal ions, etc. contained in coffee, black tea, Japanese tea and the like.
従来、ステインを除去することを目的として、ステインの溶解作用を有するポリエチレングリコールやポリビニルピロリドン等を配合した口腔用組成物や、当該成分にさらに別の成分を組み合わせた口腔用組成物が知られている(例えば、特許文献1参照。)。
また、特定の構造を有するスルホコハク酸系界面活性剤からなるステイン形成阻害用口腔用組成物が提案されている(例えば、特許文献2参照。)。
Conventionally, for the purpose of removing stains, oral compositions in which polyethylene glycol or polyvinylpyrrolidone having a stain-dissolving action is blended, and oral compositions in which another component is combined with the component are known. (For example, refer to Patent Document 1).
Moreover, the composition for oral cavity for stain formation inhibition which consists of sulfosuccinic-acid type surfactant which has a specific structure is proposed (for example, refer patent document 2).
しかし、特許文献1に記載されたような口腔用組成物は十分なステイン除去効果が得られないという問題点があった。また、特許文献2に記載のステイン形成阻害用口腔用組成物においては、味や香りがよくない、刺激が感じられるなど使用感が悪いという問題点があった。 However, the oral composition as described in Patent Document 1 has a problem that a sufficient stain removal effect cannot be obtained. In addition, the oral composition for inhibiting stain formation described in Patent Document 2 has a problem that the taste and aroma are not good and the feeling of use is bad, such as irritation.
この他にもステインの形成を阻害する成分は種々検討されてはいるが、十分なステイン形成阻害効果と、良好な使用感とを同時に満足するものはなく、依然として検討の必要性があった。 In addition to this, various components that inhibit the formation of stains have been studied, but none of them satisfy both a sufficient stain formation inhibitory effect and a good feeling of use at the same time, and there is still a need for investigation.
そこで本発明の目的は、十分なステイン形成阻害効果と、良好な使用感とを有する口腔用ステイン形成阻害剤および該口腔用ステイン形成阻害剤を含有した口腔用組成物を提供することにある。 Therefore, an object of the present invention is to provide an oral stain formation inhibitor having a sufficient stain formation inhibitory effect and a good feeling of use, and an oral composition containing the oral stain formation inhibitor.
本発明者らは鋭意研究を重ねた結果、特定の成分によって十分なステイン形成阻害効果および良好な使用感を両立できることを見出し、本発明を完成するに至った。
すなわち本発明は以下の通りである。
(1)テトラデセンスルホン酸ナトリウムからなることを特徴とする口腔用ステイン形成阻害剤。
(2)前記(1)に記載の口腔用ステイン形成阻害剤を配合したことを特徴とする口腔用組成物。
As a result of intensive studies, the present inventors have found that a specific component can achieve both a sufficient stain formation inhibitory effect and a good feeling of use, and have completed the present invention.
That is, the present invention is as follows.
(1) An oral stain formation inhibitor comprising sodium tetradecenesulfonate.
(2) An oral composition comprising the oral stain formation inhibitor according to (1).
本発明の口腔用ステイン形成阻害剤は、テトラデセンスルホン酸ナトリウムからなり、十分なステイン形成阻害効果と、味や香りに影響することなく、不快な刺激を感じることもなく、良好な使用感を有する。よって本発明の口腔用ステイン形成阻害剤は、ステインの形成阻害を目的とする口腔用組成物に好適に用いることができる。 The oral stain formation inhibitor of the present invention is composed of sodium tetradecene sulfonate, has a sufficient stain formation inhibitory effect, does not affect the taste and aroma, does not feel unpleasant stimulation, and has a good feeling of use Have. Therefore, the oral stain formation inhibitor of the present invention can be suitably used for an oral composition intended to inhibit the formation of stain.
以下、本発明をさらに詳細に説明する。
本発明の口腔用ステイン形成阻害剤は、テトラデセンスルホン酸ナトリウム(別称、オレフィン(C14−16)スルホン酸ナトリウム)からなるものである。そして本発明は、テトラデセンスルホン酸ナトリウムが優れたステイン形成阻害効果を有するとの新たな知見にもとづいてなされたものである。
Hereinafter, the present invention will be described in more detail.
The oral stain formation inhibitor of the present invention comprises sodium tetradecene sulfonate (also referred to as olefin (C14-16) sodium sulfonate). And this invention is made | formed based on the new knowledge that sodium tetradecene sulfonate has the outstanding stain formation inhibitory effect.
本発明の口腔用ステイン形成阻害剤を口腔内に適用することで、テトラデセンスルホン酸ナトリウムがステイン形成の原因となる着色物質の蓄積を抑制して、歯面にステインが付着するのを防ぐことができるものと考えられる。 By applying the oral stain formation inhibitor of the present invention to the oral cavity, sodium tetradecenesulfonate suppresses the accumulation of coloring substances that cause stain formation, and prevents the stain from adhering to the tooth surface. Can be considered.
本発明の口腔用ステイン形成阻害剤は、洗口液、液体歯磨き、口中清涼剤、うがい薬(含嗽剤)、液状歯磨きおよび練り歯磨きなどの歯磨き類、トローチ、チューインガム等の各種口腔用組成物に配合して用いることができる。
これらの中でも、本発明の効果が良好に奏されるという観点から、洗口液、液状歯磨き、口中清涼剤などの液体製剤の形態として用いることが好ましい。これらは公知の手段により製剤とすることができる。
The oral stain formation inhibitor of the present invention is applied to various oral compositions such as mouthwashes, liquid toothpastes, mouth fresheners, mouthwashes (gargles), liquid toothpastes and toothpastes, troches, chewing gums and the like. It can mix | blend and use.
Among these, from the viewpoint that the effects of the present invention are satisfactorily achieved, it is preferably used as a form of a liquid preparation such as a mouthwash, liquid toothpaste, or mouth freshener. These can be made into preparations by known means.
前記口腔用組成物に本発明の口腔用ステイン形成阻害剤を用いる際には、該口腔用組成物の形態にあわせて配合量を適宜調整すればよく、例えば、口腔用組成物中、0.005質量%以上、好ましくは0.01質量%以上とすることで、十分なステイン形成阻害効果を得ることができる。また発泡性を抑えて使用感をよくするため口腔用組成物中、2質量%以下、好ましくは1質量%以下とするのがよい。さらに好適には0.03〜0.5質量%とするのがよい。 When the oral stain formation inhibitor of the present invention is used in the oral composition, the blending amount may be appropriately adjusted according to the form of the oral composition. By setting the content to 005% by mass or more, preferably 0.01% by mass or more, a sufficient stain formation inhibitory effect can be obtained. Moreover, in order to suppress foaming and improve usability, the composition for oral cavity is 2% by mass or less, preferably 1% by mass or less. More preferably, it is good to set it as 0.03-0.5 mass%.
また、前記口腔用組成物とするに際しては、必要に応じて公知の各種添加剤を配合することができる。
例えば、フッ化ナトリウム、モノフルオロリン酸ナトリウム等のフッ化物;アズレン、アズレンスルホン酸塩、β−グリチルレチン酸、グリチルリチン酸及び塩類、ジヒドロコレステロール、エピジヒドロコレステリン、オウバクエキス、トウキエキス、酢酸dl−α−トコフェロール、ε−アミノカプロン酸、トラネキサム酸等の抗炎症剤;塩化セチルピリジニウム、塩化ベンザルコニム、塩化ベンゼトニウム、クロルヘキシジン塩、トリクロサン、イソプロピルメチルフェノール、塩酸アルキルジアミノエチルグリシン等の殺菌剤;ガントレッツ酸、塩化亜鉛、有機酸亜鉛等の歯石予防剤;ヒノキチオール、アラントイン、アラントインクロルヒドロキシアルミニウム、アラントインジヒドロキシアルミニウム、塩化ナトリウム等の収斂剤;グリセリン、ソルビトール、ポリエチレングリコール等の湿潤剤;ラウリル硫酸ナトリウム等の発泡剤;ピネン、ペパーミント油、シナモンオイル、グローブオイル、オイゲノール、レモンオイル、バニリン、シネオール、ユーカリオイル等の香料;サッカリン、サッカリンナトリウム、キシリトール、エリストール、ソルビトール、ステビア等の甘味料;青色1号、黄色5号、黄色4号、黄色202(1)号、緑色3号、緑色201号、赤色102号等の着色剤;パラベン類、安息香酸ナトリウム、パラオキシ安息香酸ブチル等の保存剤;リン酸一ナトリウム、リン酸二ナトリウム等のpH調整剤;POE硬化ヒマシ油、POE・POPブロックポリマー、POE・POPアルキルエーテル、POEアルキルエーテル、POEアルキルフェニルエーテル、POE脂肪酸エステル、POE高級アルコールエーテル、POE・POP脂肪酸エステル、POEソルビタン脂肪酸エステル、ソルビタン脂肪酸エステル、グリセリン脂肪酸エステル、ポリグリセリン脂肪酸エステル、プロピレングリコール脂肪酸エステル等の非イオン性界面活性剤;ラウリル硫酸ナトリウム、ミリスチル硫酸ナトリウム、POEアルキルエーテル硫酸塩、ラウロイルサルコシナトリウム、ミリストイルサルコシンナトリウム、アルキルエーテルカルボン酸塩、アルキルリン酸塩、POEアルキルエーテルリン酸塩、N−アシルタウリン塩、POEアルキルエーテルリン酸・リン酸塩、スルホン酸塩等のアニオン性界面活性剤;塩化アルキルトリメチルアンモニウム、塩化ジアルキルジメチルアンモニウム、塩化セチルピリジニウム、塩化ベンゼトニウム、塩化ベンザルコニウム、POEアルキルアミン・脂肪酸アミド等のカチオン性界面活性剤等が挙げられる。
Moreover, when setting it as the said composition for oral cavity, various well-known additives can be mix | blended as needed.
For example, fluorides such as sodium fluoride and sodium monofluorophosphate; azulene, azulene sulfonate, β-glycyrrhetinic acid, glycyrrhizic acid and salts, dihydrocholesterol, epidihydrocholesterin, buckwheat extract, sugar beet extract, dl-acetate Anti-inflammatory agents such as α-tocopherol, ε-aminocaproic acid, tranexamic acid; bactericides such as cetylpyridinium chloride, benzalkonium chloride, benzethonium chloride, chlorhexidine salt, triclosan, isopropylmethylphenol, alkyldiaminoethylglycine hydrochloride; gantrezic acid, chloride Anticalculus agents such as zinc and organic acid zinc; astringents such as hinokitiol, allantoin, allantochlorohydroxyaluminum, allantoindihydroxyaluminum, sodium chloride Wetting agents such as glycerin, sorbitol, polyethylene glycol; foaming agents such as sodium lauryl sulfate; fragrances such as pinene, peppermint oil, cinnamon oil, glove oil, eugenol, lemon oil, vanillin, cineol, eucalyptus oil; saccharin, sodium saccharin, xylitol Sweeteners such as erythritol, sorbitol, stevia; colorants such as blue No. 1, yellow No. 5, yellow No. 4, yellow 202 (1), green No. 3, green No. 201, red No. 102; parabens, Preservatives such as sodium benzoate and butyl paraoxybenzoate; pH adjusters such as monosodium phosphate and disodium phosphate; POE hydrogenated castor oil, POE / POP block polymer, POE / POP alkyl ether, POE alkyl ether, POE Alkylfe Nonionic surfactants such as ether, POE fatty acid ester, POE higher alcohol ether, POE / POP fatty acid ester, POE sorbitan fatty acid ester, sorbitan fatty acid ester, glycerin fatty acid ester, polyglycerin fatty acid ester, propylene glycol fatty acid ester; lauryl sulfate Sodium, myristyl sulfate, POE alkyl ether sulfate, lauroyl sarcosine sodium, myristoyl sarcosine sodium, alkyl ether carboxylate, alkyl phosphate, POE alkyl ether phosphate, N-acyl taurate, POE alkyl ether phosphate・ Anionic surfactants such as phosphates and sulfonates; alkyltrimethylammonium chloride, dialkyldimethylammonium chloride, Cetylpyridinium, benzethonium chloride, benzalkonium chloride, cationic surfactants such as POE alkylamine, fatty acid amides.
例えば、洗口液とするには、水およびエタノール等を溶剤とし、前記のような所期の添加剤を用いて常法によって調製すればよい。例えば、洗口液は、各成分を撹拌下で順次混合することで調製することができる。
またpH調整剤を用いてpHを5〜10とすると口腔内での使用感がさらに良好となる。さらにエタノールの使用量を洗口液全量に対して25質量%以下、好ましくは10%以下の範囲とすると口腔内での刺激を抑えることができるので好ましい。
For example, in order to make a mouthwash, water and ethanol may be used as a solvent and prepared by a conventional method using the desired additives as described above. For example, the mouthwash can be prepared by sequentially mixing the components under stirring.
Moreover, when the pH is adjusted to 5 to 10 using a pH adjuster, the usability in the oral cavity is further improved. Furthermore, it is preferable that the amount of ethanol used is 25% by mass or less, preferably 10% or less, based on the total amount of the mouthwash, since irritation in the oral cavity can be suppressed.
以下、実施例および比較例により本発明をさらに説明するが、本発明は下記例に何ら制限されるものではない。 EXAMPLES Hereinafter, although an Example and a comparative example demonstrate this invention further, this invention is not restrict | limited to the following example at all.
<試験例1:ステイン形成阻害確認試験>
(基剤の調製)
下記表1に記載した各成分を、室温下(約25℃)で撹拌下、混合・溶解し、基剤を調製した。
<Test Example 1: Stain formation inhibition confirmation test>
(Preparation of base)
Each component described in the following Table 1 was mixed and dissolved under stirring at room temperature (about 25 ° C.) to prepare a base.
(検体の調製)
上記で得られた基剤99.5w/v%に、下記表2に示す成分0.5w/v%を混合し、検体1〜4を調製した。
(Sample preparation)
Samples 1 to 4 were prepared by mixing 99.5 w / v% of the base obtained above and 0.5 w / v% of the components shown in Table 2 below.
得られた検体1〜4および基剤からなる検体5に対し、下記のステイン形成阻害確認試験を行った。
(テストプレートの作成)
下記(1)〜(2)の工程を順次行うことにより、テストプレートを作成した。
(1)ハイドロキシアパタイトプレート(HAP)10mm×10mmの片面を耐水性研磨紙(1000番)で研磨した。
(2)研磨したHAPを、0.12%の塩酸に30秒間、次いで過飽和の炭酸ナトリウム水溶液に30秒間浸漬した後、最後に蒸留水で中和してテストプレートを作成した。
The following stain formation inhibition confirmation test was performed on the obtained samples 1 to 4 and the sample 5 including the base.
(Create test plate)
A test plate was prepared by sequentially performing the following steps (1) to (2).
(1) One side of a hydroxyapatite plate (HAP) 10 mm × 10 mm was polished with water-resistant abrasive paper (# 1000).
(2) The polished HAP was immersed in 0.12% hydrochloric acid for 30 seconds, then in a supersaturated aqueous sodium carbonate solution for 30 seconds, and finally neutralized with distilled water to prepare a test plate.
(試験の手順)
下記(i)〜(vi)の工程を順次行い、これを10回繰り返してサンプルを調製した。
(i)ヒト唾液3mLにテストプレートを1時間浸漬する。
(ii)さらに1%グルコン酸クロルヘキシジン水溶液3mLにテストプレートを1分間浸漬する。
(iii)テストプレートを検体3mLに浸漬し、穏やかに30秒間揺らす。
(iv)0.57%クエン酸鉄(III)アンモニウム水溶液3mLにテストプレートを30秒間浸漬する。
(v)濃厚な紅茶抽出液3mLにテストプレートを20分間浸漬する。
(vi)テストプレートを水中で穏やかに揺らしながら30秒間水洗する。
(Examination procedure)
The following steps (i) to (vi) were sequentially performed, and this was repeated 10 times to prepare a sample.
(I) Immerse the test plate in 3 mL of human saliva for 1 hour.
(Ii) The test plate is further immersed in 3 mL of a 1% aqueous solution of chlorhexidine gluconate for 1 minute.
(Iii) Immerse the test plate in 3 mL of specimen and gently shake for 30 seconds.
(Iv) The test plate is immersed in 3 mL of 0.57% aqueous solution of ammonium iron (III) citrate for 30 seconds.
(V) Immerse the test plate in 3 mL of concentrated black tea extract for 20 minutes.
(Vi) Wash the test plate with water for 30 seconds while gently shaking in water.
(ステイン形成阻害率の算出)
試験前のHAPの研磨面と試験後のHAPの研磨面をそれぞれ色差計(コニカミノルタ株式会社製「CR−321」)で測定し、L値(明度)を算出し、下記の計算式によってステイン形成阻害率を算出した。なお、L値の算出は3回繰り返し、その平均値を求めた。結果を表3に示す。
ステイン形成阻害率(%)=(L2/L1)×100
(式中、L1は試験前のHAPの研磨面のL値であり、L2は試験後のHAPの研磨面のL値である。)
(Calculation of stain formation inhibition rate)
The HAP polished surface before the test and the polished HAP polished surface after the test were each measured with a color difference meter (“CR-321” manufactured by Konica Minolta Co., Ltd.), and the L value (lightness) was calculated. The formation inhibition rate was calculated. In addition, calculation of L value was repeated 3 times and the average value was calculated | required. The results are shown in Table 3.
Stain formation inhibition rate (%) = (L2 / L1) × 100
(In the formula, L1 is the L value of the polished surface of the HAP before the test, and L2 is the L value of the polished surface of the HAP after the test.)
表3の結果から、本発明のテトラデセンスルホン酸ナトリウムからなる口腔用ステイン形成阻害剤は、ステインの形成阻害作用があるとされる他の成分に比べて、優れたステイン形成阻害効果を有することが分かった。また浸漬して軽く振盪するだけで高いステイン形成阻害率が得られたことから、口腔内をすすいで使用する洗口液などの液体製剤に適用するのが好適であることがわかった。 From the results of Table 3, the oral stain formation inhibitor comprising sodium tetradecenesulfonate of the present invention has an excellent stain formation inhibitory effect compared to other components that are considered to have a stain formation inhibitory effect. I understood. Moreover, since a high stain formation inhibition rate was obtained only by immersing and lightly shaking, it was found that it is suitable to apply to a liquid preparation such as a mouthwash used by rinsing the oral cavity.
<試験例2:官能評価>
(基剤の調製)
試験例1と同様にして基剤を調製した。
<Test Example 2: Sensory evaluation>
(Preparation of base)
A base was prepared in the same manner as in Test Example 1.
(検体の調製)
得られた基剤99.5w/v%に、下記表4に示す成分0.5w/v%を混合し、各種検体6〜12を調製した。また基剤のみからなるものを検体13とした。
(Sample preparation)
The obtained base 99.5 w / v% was mixed with components 0.5 w / v% shown in Table 4 below to prepare various specimens 6-12. A sample consisting only of the base was designated as Sample 13.
得られた検体6〜13のそれぞれに対し、官能評価を行なった。
官能評価は、6名のパネラーにより、香り、味、刺激感について以下の評価基準で判定を行い、平均スコアが4点以上を「◎」、3点以上4点未満を「○」、2点以上3点未満を「△」、1点以上2点未満を「×」とした。結果を表5に示す。
〔評価基準〕
5点:非常によい
4点:よい
3点:ふつう
2点:わるい
1点:非常にわるい
Sensory evaluation was performed on each of the obtained specimens 6 to 13.
The sensory evaluation is performed by 6 panelists to determine the aroma, taste, and irritation based on the following evaluation criteria, with an average score of 4 or higher: “◎”, 3 or higher but less than 4: “○”, 2 points Above 3 points were set as “Δ”, and above 1 point and below 2 points were set as “X”. The results are shown in Table 5.
〔Evaluation criteria〕
5 points: very good 4 points: good 3 points: normal 2 points: bad 1 point: very bad
表5の結果から、本発明のテトラデセンスルホン酸ナトリウムからなる口腔用ステイン形成阻害剤を用いた検体6は、香り、味、刺激感の全てにおいて非常に良好であることが示された。また、検体6は、その他の成分を用いた検体7〜12と比べても、香り、味がよく、さらに刺激感もほどよく、優れた使用感を得ることができることがわかった。 From the results shown in Table 5, it was shown that the specimen 6 using the oral stain formation inhibitor composed of sodium tetradecenesulfonate of the present invention was very good in all of the aroma, taste and irritation. In addition, it was found that the specimen 6 has a good fragrance and taste, and a moderate irritation feeling as compared with the specimens 7 to 12 using other components, and an excellent usability can be obtained.
<参考試験例:ステイン形成阻害確認試験>
(検体の調製)
下記表6に記載した各成分を、室温下(約25℃)で撹拌下、混合・溶解し、検体14、15を調製した。
<Reference test example: Stain formation inhibition confirmation test>
(Sample preparation)
Samples 14 and 15 were prepared by mixing and dissolving the components described in Table 6 below at room temperature (about 25 ° C.) with stirring.
得られた検体14、15に対し、下記のステイン形成阻害確認試験を行った。
(テストプレートの作成)
下記(1)〜(2)の工程を順次行うことにより、テストプレートを作成した。
(1)ハイドロキシアパタイトプレート(HAP)10mm×10mmの片面を耐水性研磨紙(1000番)で研磨した。
(2)研磨したHAPを、0.12%の塩酸に30秒間、次いで過飽和の炭酸ナトリウム水溶液に30秒間浸漬した後、蒸留水で中和しテストプレートを作成した。
(試験の手順)
下記(i)〜(vi)の工程を順次行い、これを10回繰り返してサンプルを調製した。
(i)ヒト唾液3mLにテストプレートを1時間浸漬する。
(ii)さらに1%グルコン酸クロルヘキシジン水溶液3mLにテストプレートを1分間浸漬する。
(iii)テストプレートを検体3mLに浸漬し、穏やかに30秒間揺らす。
(iv)0.57%クエン酸鉄(III)アンモニウム水溶液3mLにテストプレートを30秒間浸漬する。
(v)濃厚な紅茶抽出液3mLにテストプレートを20分間浸漬する。
(vi)テストプレートを水中で穏やかに揺らしながら30秒間水洗する。
The obtained specimens 14 and 15 were subjected to the following stain formation inhibition confirmation test.
(Create test plate)
A test plate was prepared by sequentially performing the following steps (1) to (2).
(1) One side of a hydroxyapatite plate (HAP) 10 mm × 10 mm was polished with water-resistant abrasive paper (# 1000).
(2) The polished HAP was immersed in 0.12% hydrochloric acid for 30 seconds and then in a supersaturated aqueous sodium carbonate solution for 30 seconds, and then neutralized with distilled water to prepare a test plate.
(Examination procedure)
The following steps (i) to (vi) were sequentially performed, and this was repeated 10 times to prepare a sample.
(I) Immerse the test plate in 3 mL of human saliva for 1 hour.
(Ii) The test plate is further immersed in 3 mL of a 1% aqueous solution of chlorhexidine gluconate for 1 minute.
(Iii) Immerse the test plate in 3 mL of specimen and gently shake for 30 seconds.
(Iv) The test plate is immersed in 3 mL of 0.57% aqueous solution of ammonium iron (III) citrate for 30 seconds.
(V) Immerse the test plate in 3 mL of concentrated black tea extract for 20 minutes.
(Vi) Wash the test plate with water for 30 seconds while gently shaking in water.
(ステイン形成阻害率の算出)
試験例1と同様にして、ステイン形成阻害率を算出した。
結果を表7に示す。
(Calculation of stain formation inhibition rate)
In the same manner as in Test Example 1, the stain formation inhibition rate was calculated.
The results are shown in Table 7.
表7の結果から、従来公知のポリエチレングリコールおよび/またはポリビニルピロリドンからなるステイン形成阻害剤は、検体1に比べて多く配合しているのにもかかわらず、ステイン形成阻害効果が不十分であった。 From the results shown in Table 7, the stain formation inhibitor composed of conventionally known polyethylene glycol and / or polyvinyl pyrrolidone was insufficient in the stain formation inhibitory effect, despite being incorporated in a larger amount than the specimen 1. .
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014050281A JP6307314B2 (en) | 2014-03-13 | 2014-03-13 | Oral stain formation inhibitor and oral composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014050281A JP6307314B2 (en) | 2014-03-13 | 2014-03-13 | Oral stain formation inhibitor and oral composition |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015174830A JP2015174830A (en) | 2015-10-05 |
JP6307314B2 true JP6307314B2 (en) | 2018-04-04 |
Family
ID=54254330
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014050281A Active JP6307314B2 (en) | 2014-03-13 | 2014-03-13 | Oral stain formation inhibitor and oral composition |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6307314B2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111417381B (en) | 2017-11-30 | 2023-06-30 | 狮王株式会社 | Oral scale remover, oral scale formation inhibitor, and oral composition |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01125315A (en) * | 1987-11-09 | 1989-05-17 | Lion Corp | Composition for oral cavity |
JP3578560B2 (en) * | 1996-07-05 | 2004-10-20 | サンスター株式会社 | Oral composition containing sulfosuccinic surfactant |
JP4109727B2 (en) * | 1996-07-05 | 2008-07-02 | サンスター株式会社 | Composition for oral cavity containing amino acid surfactant |
JPH1129453A (en) * | 1997-07-04 | 1999-02-02 | Lion Corp | Composition for cleaning interior of oral cavity |
GB201004981D0 (en) * | 2010-03-24 | 2010-05-12 | Glaxo Group Ltd | Novel use |
JP6007781B2 (en) * | 2011-12-26 | 2016-10-12 | ライオン株式会社 | Oral composition and oral biofilm remover |
-
2014
- 2014-03-13 JP JP2014050281A patent/JP6307314B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2015174830A (en) | 2015-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6270659B2 (en) | Stain adhesion inhibitor and oral composition | |
JP5613990B2 (en) | Tooth dentinal tubule sealant and oral composition | |
KR20120002533A (en) | Methods for improving taste and oral care compositions with improved taste | |
JPH0665034A (en) | Detergent composition for oral cavity | |
JP2011098920A (en) | Dentifrice composition | |
WO2012124533A1 (en) | Liquid oral composition with two separate layers | |
JP2009149537A (en) | Oral composition | |
JP2006347986A (en) | Composition for oral cavity | |
JP6307314B2 (en) | Oral stain formation inhibitor and oral composition | |
CN107205892B (en) | Oral composition effective in inhibiting tartar formation | |
JP2002255769A (en) | Composition for oral cavity cleaning | |
JP6038567B2 (en) | Oral composition | |
JP2012232937A (en) | Composition for oral cavity | |
JP2000178150A (en) | Liquid composition for oral cavity | |
KR102579556B1 (en) | Oral composition | |
JPH1112144A (en) | Liquid oral composition | |
JP2000026257A (en) | Oral composition | |
JPH1017443A (en) | Sulfosuccinic acid-based surfactant-containing composition for oral cavity | |
JP2610444B2 (en) | Oral composition | |
KR20050078531A (en) | Composition for inhibiting halitosis | |
JP2000053547A (en) | Composition for oral cavity | |
JP3838604B2 (en) | Liquid oral composition | |
JP7385714B1 (en) | Tooth stain prevention compositions and their use | |
JP3803869B2 (en) | Oral composition | |
KR102642592B1 (en) | Oral composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20161021 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170816 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170822 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20171018 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171218 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20171218 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180227 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180312 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6307314 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |